陶氏病
药物发现
τ蛋白
临床试验
神经科学
疾病
药品
医学
生物信息学
蛋白质聚集
计算生物学
药物开发
生物信息学
阿尔茨海默病
药理学
生物
神经退行性变
病理
基因
生物化学
作者
Johanna Giovannini,Willy Smeralda,Marie Jouanne,Jana Sopková‐de Oliveira Santos,Marco Catto,Anne Sophie Voisin‐Chiret
标识
DOI:10.1016/j.drudis.2022.01.009
摘要
Tauopathies are neurodegenerative disorders associated with the accumulation of abnormal tubulin associated unit (tau) protein in the brain. Tau pathologies include a broad spectrum of diseases, with Alzheimer's disease (AD) being the most common tauopathy. The pathophysiological mechanisms of AD are still only partially understood. As a consequence, attempts to establish therapeutic approaches have led to numerous clinical trial failures and, to date, no curative treatment is available for AD despite the considerable number of research programs. Therefore, over the past decade, the aggregation of the tau protein in AD has become a therapeutic target of interest. In this review, we gather in silico, in vitro, and in vivo methodologies that are relevant to assess compounds targeting tau aggregation, from early drug design to clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI